Free Trial

Eva Fortea Analyst Performance

Analyst at Wells Fargo & Company

Eva Fortea is a stock analyst at Wells Fargo & Company in the medical sector, covering 4 publicly traded companies. Over the past year, Eva Fortea has issued 4 stock ratings, including buy and hold recommendations. While full access to Eva Fortea's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Eva Fortea's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
4 Last 0 Years
Buy Recommendations
75.00% 3 Buy Ratings
Companies Covered
4 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy75.0%3 ratings
Hold25.0%1 ratings
Sell0.0%0 ratings

Out of 4 total stock ratings issued by Eva Fortea at Wells Fargo & Company, the majority (75.0%) have been Buy recommendations, followed by 25.0% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
75.0% of companies on NASDAQ
3 companies
NYSE
25.0% of companies on NYSE
1 company

Eva Fortea, an analyst at Wells Fargo & Company, currently covers 4 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
4 companies
100.0%

Eva Fortea of Wells Fargo & Company specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
3 companies
75.0%
MED - DRUGS
1 company
25.0%

Eva Fortea's Ratings History at Wells Fargo & Company

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
9/11/2025Boost Price Target$40.45$70.00Overweight
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
8/7/2025Lower Price Target$10.13$11.00Equal Weight
Xencor, Inc. stock logo
XNCR
Xencor
8/7/2025Lower Price Target$7.19$27.00Overweight
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
8/7/2025Lower Price Target$9.35$25.00Overweight